Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di... : vimarsana.com

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di...

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou...

Related Keywords

United States , Japan , Calgary , Alberta , Canada , California , San Diego , Spring House , British Columbia , Horsham , Saskatchewan , Americans , Canadian , Taylor Francis , Remo Panaccione , Bridget Kimmel , Jan Wehkamp , Crohn Colitis Foundation , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , National Cancer Institute Surveillance , End Results Program , Japan Pharmaceuticals , None Of The Janssen Pharmaceutical Companies , National Institutes Of Health Surveillance , Drug Administration , Exchange Commission , Companies Of Johnson , University Of Calgary , European Medicines Agency , Canadian Agency For Drugs Technologies In Health , Devices Agency , Johnson , Digestive Disease , Inflammatory Bowel Disease Unit , Janssen Global Trial Finder , National Institutes , Health Surveillance , End Results , Vice President , Gastroenterology Disease Area Leader , Janssen Research , Simple Endoscopic Score , Disease Activity Index , Ulcerative Colitis , Prescribing Information , Medication Guidefor , Reversible Encephalopathy Syndrome , Medication Guide , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Guselkumab Maintenance Therapy , Severely Active Crohn , Biologic Failure , Pooled Safety Analysis Through , Cumulative Safety , Patients Treated , Long Term Pooled Safety Analysis , Accessed May , Achieved Clinical Remission , Corticosteroid Free Remission Through , Cancer Institute Surveillance , Statistics Review , Incidence Ratio , Participants With Moderately , Monoclonal Antibody Specific , Study Conducted , Active Psoriatic , Canadian Agency , Medical Devices , Tremfya Report ,